This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Trends and Characteristics of New Drug Approvals in China, 2011–2021
Therapeutic Innovation & Regulatory Science Open Access 02 November 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information
China's drug regulatory system reform timeline (May 2015 to May 2018)* (PDF 108 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Xu, L., Gao, H., Kaitin, K. et al. Reforming China's drug regulatory system. Nat Rev Drug Discov 17, 858–859 (2018). https://doi.org/10.1038/nrd.2018.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.150
This article is cited by
-
A fast retrieval method of drug information based on multidimensional data analysis
Soft Computing (2023)
-
Trends and Characteristics of New Drug Approvals in China, 2011–2021
Therapeutic Innovation & Regulatory Science (2023)
-
Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China
Therapeutic Innovation & Regulatory Science (2023)
-
The drug lag issue: a 20-year review of China
Investigational New Drugs (2021)
-
Drivers of Start-Up Delays in Global Randomized Clinical Trials
Therapeutic Innovation & Regulatory Science (2021)